Improving phase ii oncology trial using best observed RECIST response as an endpoint by modelling continuous tumour measurements
Crossref DOI link: https://doi.org/10.1186/1745-6215-16-S2-P63
Published Online: 2015-11-16
Published Print: 2015-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Lin, Chien-Ju
Wason, James
Text and Data Mining valid from 2015-11-16
Version of Record valid from 2015-11-16
Article History
First Online: 16 November 2015